Cadrenal Therapeutics CVKD
NASDAQ CVKD
$1.60 +0.00 (+0.00%)
As of: Aug 21, 2026 · 12:40 PM EDT

Cadrenal Therapeutics (CVKD) Debt Ratio (2022)

Cadrenal Therapeutics (CVKD) posted Debt Ratio of 0.32 for Q4 2022.

Cadrenal Therapeutics (CVKD) Debt Ratio (2022) Analysis & Trends

Cadrenal Therapeutics has reported Debt Ratio for 1 years, with the latest figure at 0.32 in Q4 2022.

  • Quarterly Debt Ratio changed N/A year-over-year to 0.32 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 0.32 (changed N/A YoY) and the FY2022 annual result came in at 0.32, changed N/A from the prior year.
  • Debt Ratio was little changed at 0.32 in Q4 2022 per CVKD's latest filing.
  • Over five years, Debt Ratio peaked at 0.32 in Q4 2022 and troughed at 0.32 in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Vertex Pharmaceuticals 139.66 Bn 131.80 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 86.52 Bn 78.53 Bn 3.93 Bn 0.05
3 Argenx Se 65.33 Bn 60.14 Bn 1.37 Bn -
4 Moderna 59.76 Bn 54.62 Bn 52.00 Mn 0.05
5 BeOne Medicines 42.15 Bn 37.05 Bn 1.53 Bn 0.12
6 Alnylam Pharmaceuticals 31.84 Bn 28.53 Bn 992.69 Mn -
7 BioNTech SE 28.23 Bn 9.84 Bn 668.28 Mn 0.03
8 Insmed 27.52 Bn 26.36 Bn 358.27 Mn 0.26
9 Royalty Pharma 27.29 Bn 26.46 Bn - 0.47
10 Cadrenal Therapeutics 4.66 Mn 2.26 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2022 0.32